Table 3.

Clinical studies of olverembatinib.

Registration Number	Types	Phase	Status	Patient Number	Intervention	Main indicators
NCT04260022	CP/AP/BP-CML and Ph+ ALL, Resistance or intolerance to at least two TKIs, BCP-ALL and LBP- CML, Resistance or intolerant to at least one second or later generation TKI	I	Recruiting	62	Blinatumomab Olverembatinib. 30, 40, 50 mg QOD	Phase 2 dose and PK/PD
NCT05376852	AP-CML and CML in lymphoid/myeloid blast crisis	II	Recruiting	40	Olverembatinib,40 mg QOD Combination with decitabine	Overall response rate (end of cycle 2)
NCT05311943	CP-CML, Resistance or intolerance to at least two second generation TKIs	III	Recruiting	40	Olverembatinib, 40 mg QOD	MMR at 12 months
NCT03883087	CP-CML with T315I mutation	II	Active, Not recruiting	41	Olverembatinib,40 mg QOD	MCyR (by the end of cycle 24)
NCT03883100	AP-CML with T315I mutation	II	Active, Not recruiting	23	Olverembatinib,40 mg QOD	MaHR (by the end of cycle 24)
NCT04126681	CP-CML, Resistance or intolerance to first and second generation TKIs	II	Active, Not recruiting	144	Olverembatinib. Hydroxyurea or Interferon-based therapy. Homoharringtonine. Imatinib, Dasatinib or Nilotinib	EFS (by the end of cycle 24)

EFS, event-free survival; PK/PD, pharmacokinetic or pharmacodynamic; BCP-ALL, Ph+ B-cell precursor (BCP) ALL; LBP, lymphoid blast phase CML (CML LBP); AUC, area under the curve; MaHR, major hematologic response. Each cycle is 28 days.